Epithelix Sàrl provides alternative in vitro solutions to animal experimentation for evaluating the effects of drugs in development and assess the toxicity of chemical compounds on the human respiratory tract.
Epithelix is a biotech company founded in March 2006 and located in Geneva, Switzerland. Its founders are experienced scientists from University of Geneva with special expertise and know-how for in vitro reconstitutions of human and animal tissues. The company, being self-financed, proved its economic viability and invested in independent research and production facilities in December 2007. The company is the European leading provider of in vitro reconstituted human respiratory tissues and related services to leading academic research laboratories. Epithelix also supplies and supports Personal Care, Medical Device, as well as Chemical and Pharmaceutical.
Epithelix developed a unique technology allowing reconstituted tissues to be maintained at a homeostatic state for a long period of time; in other words, the tissues resemble the native tissue both morphologically and functionally (see our products page). The company focused initially on the respiratory system and marketed MucilAir™, the only human respiratory epithelium model able to remain fully differentiated and functional for more than one year. This model is commercialized and available in US, Europe and Asia.
Although we are mainly involved in the in vitro solutions for preclinical researches, we are also active in several research projects related to clinical therapeutic purposes, for treating patients suffering from respiratory diseases such as cancers.
Using its own commercialized products, Epithelix also offers, as a CRO, innovative in vitro testing services in its laboratory (see our services page).
Epithelix is headquartered in Plan-les-Ouates, close to Geneva, Switzerland with a subsidiary in France. Epithelix has been recognized for its scientific and commercial achievements with a number of national and international awards.